Accreditation: It's a FACT at CHI Health Immanuel
In every aspect of autologous stem-cell transplant work, CHI Health Immanuel in Omaha meets the most rigorous standards. Thus, the Foundation for the Accreditation of Cellular Therapy (FACT) has awarded Immanuel internationally recognized certification for six years.
“FACT accreditation validates that we provide exceptional care for patients with blood cancers,” said Samer Renno, MD, hematologist/oncologist and director of the CHI Health autologous stem-cell transplant program. “We have a multidisciplinary stem-cell transplant team that provides high-quality, state-of-the-art treatment. We design individualized care plans to treat each patient.”
FACT is the oversight organization that inspects to assure that stem-cell transplant policies and procedures are up to standards. Specifically, this regards collection, storage and re-administration of cells, as well as patient care before, during and after infusion of cells.
“The standards for accreditation are evidence-based requirements that have been set by world-renowned experts in cellular therapy,” Dr. Renno said.
In an autologous transplant, a patient’s own blood stem cells are removed from bone marrow or peripheral blood in the weeks before treatment. These cells are frozen and stored while the patient gets treatment (high-dose chemotherapy and/or radiation) and then infused back into the patient’s bloodstream by IV. This is a common type of transplant for certain types of cancer, including multiple myeloma and non-Hodgkins lymphoma.